Focused On-demand Library for Doublecortin domain-containing protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UHG0

UPID:

DCDC2_HUMAN

Alternative names:

Protein RU2S

Alternative UPACC:

Q9UHG0; Q5VTR8; Q5VTR9; Q86W35; Q9UFD1; Q9UHG1; Q9ULR6

Background:

Doublecortin domain-containing protein 2, also known as Protein RU2S, plays a pivotal role in the inhibition of the canonical Wnt signaling pathway, crucial for cell fate determination, migration, and organogenesis. This protein is also implicated in neuronal migration during cerebral neocortex development and is vital for ciliogenesis and maintaining ciliary length, essential for cellular signaling and homeostasis.

Therapeutic significance:

Protein RU2S is associated with a spectrum of diseases, including Dyslexia 2, Nephronophthisis 19, autosomal recessive Deafness 66, and neonatal Sclerosing cholangitis. These associations highlight its potential as a therapeutic target for cognitive disorders, kidney and liver diseases, and hearing loss. Understanding the role of Protein RU2S could open doors to potential therapeutic strategies.